Tango Therapeutics, Inc. (TNGX)
TNGXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$25.50
+0.8300 (+3.36%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $4.32bn
- P/E
- –
- EPS, last 4 quarters
- $-1.37
- Dividend yield
- –
- Day range
- –
- 52-week range
- $7.49 to $34.39
- Average volume
- –
- Previous close
- $24.67
Analysts
9 coveringBuy7 buy, 2 hold, 0 sell
Targets a year out average $45.14, +77.0% from here
Earnings
next estimate $-0.3900Next report
Dec 2025
+6.5%
Mar 2026
0.0%
Jun 2026
-19.4%
Sep 2026
-14.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$41.86m | -$48.77m | -$59.79m | -$78.12m |
| Net income | -$38.75m | -$45.51m | -$55.34m | -$68.39m |
News
8 latest- Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business HighlightsFintel · 4 days ago
- Tango, Erasca Open Phase 1/2 Combination Trial Enrollment In Pancreatic And Lung Cancers RTTNews · Nov 5, 2026
- TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataZacks · Oct 26, 2026
- Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response RateMarketBeat · Oct 23, 2026
- Tango Therapeutics Maps 2027 Phase 3 Trial After Promising Cancer Data;Stock Down In Pre-Market RTTNews · Oct 23, 2026
- Tango Therapeutics Reports 82% Response Rate In Pancreatic Cancer Trial RTTNews · Oct 23, 2026
- Tango Therapeutics, Inc. Announces Phase 1/2 Vopimetostat Trial Results and 14% Workforce ReductionFintel · Oct 23, 2026
- Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?Zacks · Sep 10, 2026
The company
Tango Therapeutics is a clinical-stage biotechnology company dedicated to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer. Using an approach that focuses on genetic vulnerabilities in cancer, Tango is pursuing PRMT5-targeted therapies designed to address pancreatic and other forms of cancer while sparing healthy normal tissues.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- tangotx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.